Ranjit Shahani, the former chief of Novartis India Ltd. and the face of the Swiss multinational in the country for over a decade, including during the tumultuous Glivec (imatinib mesylate) patent battle years, has died aged 74.
Obituary: Ranjit Shahani, Ex-Novartis India Chief Who ‘Traveled Light’
Industry veteran and mentor to many, Ranjit Shahani steered Novartis India with seeming calm through a rocky phase when the Glivec patent case ruling didn't go the Swiss multinational's way - perhaps not unusual for someone who had seen the ebbs and flows of life closely when his parents moved to India as refugees from Pakistan.
More from Leadership
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.